Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17078
Country/Region: Uganda
Year: 2016
Main Partner: University Research Corporation, LLC
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $10,872,533 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,020,682
Care: Orphans and Vulnerable Children (HKID) $100,000
Care: TB/HIV (HVTB) $451,857
Care: Pediatric Care and Support (PDCS) $921,611
Laboratory Infrastructure (HLAB) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $395,591
Testing: HIV Testing and Counseling (HVCT) $637,364
Sexual Prevention: Other Sexual Prevention (HVOP) $886,168
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $811,975
Treatment: Adult Treatment (HTXS) $4,252,017
Treatment: Pediatric Treatment (PDTX) $395,268
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 149
GEND_GBV Age/Sex: <10 Female 2017 286
GEND_GBV Age/Sex: <10 Male 2017 93
GEND_GBV Age/Sex: <10 Male 2017 168
GEND_GBV Age/Sex: 10-14 Female 2017 421
GEND_GBV Age/Sex: 10-14 Female 2017 797
GEND_GBV Age/Sex: 10-14 Male 2017 93
GEND_GBV Age/Sex: 10-14 Male 2017 168
GEND_GBV Age/Sex: 15-19 Female 2017 745
GEND_GBV Age/Sex: 15-19 Female 2017 1,412
GEND_GBV Age/Sex: 15-19 Male 2017 148
GEND_GBV Age/Sex: 15-19 male 2017 290
GEND_GBV Age/Sex: 20-24 Female 2017 743
GEND_GBV Age/Sex: 20-24 Female 2017 1,413
GEND_GBV Age/Sex: 20-24 Male 2017 149
GEND_GBV Age/Sex: 20-24 Male 2017 286
GEND_GBV Age/Sex: 25-49 Female 2017 301
GEND_GBV Age/Sex: 25-49 Female 2017 571
GEND_GBV Age/Sex: 25-49 Male 2017 149
GEND_GBV Age/Sex: 25-49 Male 2017 286
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 272
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 514
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 657
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 1,249
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 2,334
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 4,428
GEND_GBV Number of people receiving post-GBV care 2017 2,991
GEND_GBV Number of people receiving post-GBV care 2017 5,677
GEND_GBV Sum of Age/Sex Disaggregates 2017 756
GEND_GBV Sum of Age/Sex Disaggregates 2017 1,419
HTS_TST Age/sex: <1 2017 2,000
HTS_TST Age/sex: <1 2017 2,574
HTS_TST Age/sex: 1-9 2017 6,567
HTS_TST Age/sex: 1-9 2017 8,499
HTS_TST Age/sex: 10-14 Female 2017 5,670
HTS_TST Age/sex: 10-14 Female 2017 7,344
HTS_TST Age/sex: 10-14 Male 2017 5,669
HTS_TST Age/sex: 10-14 Male 2017 7,341
HTS_TST Age/sex: 15-19 Female 2017 20,164
HTS_TST Age/sex: 15-19 Female 2017 30,473
HTS_TST Age/sex: 15-19 Male 2017 12,577
HTS_TST Age/sex: 15-19 Male 2017 18,123
HTS_TST Age/sex: 20-24 Female 2017 30,257
HTS_TST Age/sex: 20-24 Female 2017 45,716
HTS_TST Age/sex: 20-24 Male 2017 18,871
HTS_TST Age/sex: 20-24 Male 2017 27,187
HTS_TST Age/sex: 25-49 Female 2017 46,391
HTS_TST Age/sex: 25-49 Female 2017 70,095
HTS_TST Age/sex: 25-49 Male 2017 28,928
HTS_TST Age/sex: 25-49 Male 2017 41,682
HTS_TST Age/sex: 50+ Female 2017 4,030
HTS_TST Age/sex: 50+ Female 2017 6,094
HTS_TST Age/sex: 50+ Male 2017 2,516
HTS_TST Age/sex: 50+ Male 2017 3,620
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 9,955
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 12,880
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 9,951
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 12,878
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 100,842
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 152,378
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 62,892
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 90,612
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 183,640
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 268,748
HTS_TST Service Delivery Point (Facility): Index testing 2017 6,066
HTS_TST Service Delivery Point (Facility): Index testing 2017 13,098
HTS_TST Service Delivery Point (Facility): Inpatient 2017 36,703
HTS_TST Service Delivery Point (Facility): Inpatient 2017 60,457
HTS_TST Service Delivery Point (Facility): Other PITC 2017 10,109
HTS_TST Service Delivery Point (Facility): Other PITC 2017 16,690
HTS_TST Service Delivery Point (Facility): Outpatient 2017 60,991
HTS_TST Service Delivery Point (Facility): Outpatient 2017 73,776
HTS_TST Service Delivery Point (Facility): Pediatric 2017 16,888
HTS_TST Service Delivery Point (Facility): Pediatric 2017 20,931
HTS_TST Service Delivery Point (Facility): PMTCT 2017 51,515
HTS_TST Service Delivery Point (Facility): PMTCT 2017 81,758
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,368
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,038
HTS_TST Sum of Age/Sex disaggregates 2017 175,073
HTS_TST Sum of Age/Sex disaggregates 2017 257,675
HTS_TST Sum of Aggregated Age/Sex <15 2017 19,906
HTS_TST Sum of Aggregated Age/Sex <15 2017 25,758
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 163,734
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 242,990
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 183,640
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 268,748
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 249
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 327
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 242
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 329
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 868
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 1,323
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 432
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 963
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 1,307
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 1,990
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 646
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 1,452
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 2,000
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 3,046
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 989
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 2,224
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 175
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 264
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 86
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 188
HTS_TST_POS Test Result by Age: Positive: <1 2017 83
HTS_TST_POS Test Result by Age: Positive: <1 2017 120
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 282
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 387
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 432
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 584
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 424
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 579
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 4,350
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 6,623
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,153
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 4,827
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 18
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 770
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 788
KP_PREV Total estimated number of key population in the catchment area 2017 1,871
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 1,676
KP_PREV_den By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) 2017 58
KP_PREV_den By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area 2017 137
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2,153
PMTCT_ART Already on ART at beginning of current pregnancy 2017 3,423
PMTCT_ART New on ART 2017 1,514
PMTCT_ART New on ART 2017 2,435
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 51,898
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 82,379
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 2,416
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,859
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 671
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,073
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 35
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 56
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 127
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 194
PMTCT_EID Sum of Infant Age disaggregates 2017 3,087
PMTCT_EID Sum of Infant Age disaggregates 2017 4,932
PMTCT_STAT By: Known positives at entry 2017 2,149
PMTCT_STAT By: Known positives at entry 2017 3,467
PMTCT_STAT By: Number of new positives identified 2017 1,708
PMTCT_STAT By: Number of new positives identified 2017 2,698
PMTCT_STAT Number of new ANC and L&D clients 2017 53,231
PMTCT_STAT Number of new ANC and L&D clients 2017 84,481
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 51,898
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 82,379
PMTCT_STAT Sum of Positives Status disaggregates 2017 3,857
PMTCT_STAT Sum of Positives Status disaggregates 2017 6,165
PP_PREV Aggregated Age/sex: <15 Female 2017 1,009
PP_PREV Aggregated Age/sex: <15 Male 2017 939
PP_PREV Aggregated Age/sex: 15+ Female 2017 23,879
PP_PREV Aggregated Age/sex: 15+ Male 2017 1,194
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 27,021
PP_PREV Total number of people in the target population 2017 37,723
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 14
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 188
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 431
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 7
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 19
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 374
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 814
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 572
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,278
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 572
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,278
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 4,415
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,234
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 219
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 433
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 676
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 1,334
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 1,339
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 2,648
TB_SCREENDX Screen Result: Screened Positive for TB 2017 1,105
TB_SCREENDX Screen Results: Screened Positive for TB 2017 558
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 1,368
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 1,213
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 16,727
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 33,950
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 8,609
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 17,482
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 1,986
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 1,768
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 27,917
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 55,186
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 43
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 99
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 607
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,375
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 53
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 128
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,106
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,491
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,809
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 4,093
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,809
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 4,093
TX_CURR Age/Sex: <1 2017 94
TX_CURR Age/Sex: <1 2017 139
TX_CURR Age/Sex: <1-9 2017 905
TX_CURR Age/Sex: 1-9 2017 627
TX_CURR Age/Sex: 10-14 Female 2017 1,452
TX_CURR Age/Sex: 10-14 Female 2017 998
TX_CURR Age/Sex: 10-14 Male 2017 1,258
TX_CURR Age/Sex: 10-14 Male 2017 862
TX_CURR Age/Sex: 15-19 Female 2017 837
TX_CURR Age/Sex: 15-19 Female 2017 1,696
TX_CURR Age/Sex: 15-19 Male 2017 258
TX_CURR Age/Sex: 15-19 Male 2017 524
TX_CURR Age/Sex: 20-24 Female 2017 7,808
TX_CURR Age/Sex: 20-24 Female 2017 3,848
TX_CURR Age/Sex: 20-24 Male 2017 3,494
TX_CURR Age/Sex: 20-24 Male 2017 1,721
TX_CURR Age/Sex: 25-49 Female 2017 22,750
TX_CURR Age/Sex: 25-49 Female 2017 11,205
TX_CURR Age/Sex: 25-49 Male 2017 12,590
TX_CURR Age/Sex: 25-49 Male 2017 6,197
TX_CURR Age/Sex: 50+ Female 2017 1,696
TX_CURR Age/Sex: 50+ Female 2017 837
TX_CURR Age/Sex: 50+ Male 2017 874
TX_CURR Age/Sex: 50+ Male 2017 433
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,368
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,986
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,213
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,768
TX_CURR Aggregated Age/Sex: 15+ Female 2017 16,727
TX_CURR Aggregated Age/Sex: 15+ Female 2017 33,950
TX_CURR Aggregated Age/Sex: 15+ Male 2017 8,609
TX_CURR Aggregated Age/Sex: 15+ Male 2017 17,482
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 27,917
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 55,186
TX_CURR Sum of age/sex disaggregates 2017 2,220
TX_CURR Sum of Age/Sex disaggregations 2017 1,095
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,581
TX_CURR Sum of Aggregated Age/Sex <15 2017 3,754
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 25,336
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 51,432
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 27,917
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 55,186
TX_NEW Aggregated Grouping by Age: <1 2017 16
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 311
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 480
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 268
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 424
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 5,872
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 9,589
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 3,043
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 4,944
TX_NEW By Age/Sex: <1 2017 26
TX_NEW By Age/Sex: 1-9 2017 142
TX_NEW By Age/Sex: 1-9 2017 217
TX_NEW By Age/Sex: 10-14 Female 2017 236
TX_NEW By Age/Sex: 10-14 Female 2017 362
TX_NEW By Age/Sex: 10-14 Male 2017 185
TX_NEW By Age/Sex: 10-14 Male 2017 299
TX_NEW By Age/Sex: 15-19 Female 2017 294
TX_NEW By Age/Sex: 15-19 Female 2017 478
TX_NEW By Age/Sex: 15-19 Male 2017 93
TX_NEW By Age/Sex: 15-19 Male 2017 148
TX_NEW By Age/Sex: 20-24 Female 2017 1,352
TX_NEW By Age/Sex: 20-24 Female 2017 2,207
TX_NEW By Age/Sex: 20-24 Male 2017 610
TX_NEW By Age/Sex: 20-24 Male 2017 988
TX_NEW By Age/Sex: 25-49 Female 2017 3,933
TX_NEW By Age/Sex: 25-49 Female 2017 6,429
TX_NEW By Age/Sex: 25-49 Male 2017 2,188
TX_NEW By Age/Sex: 25-49 Male 2017 3,561
TX_NEW By Age/Sex: 50+ Female 2017 293
TX_NEW By Age/Sex: 50+ Female 2017 475
TX_NEW By Age/Sex: 50+ Male 2017 152
TX_NEW By Age/Sex: 50+ Male 2017 247
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 9,494
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 15,437
TX_NEW Sum of Age/Sex disaggregates 2017 9,336
TX_NEW Sum of Age/Sex disaggregates 2017 15,194
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 9,494
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 15,437
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 22,331
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 44,148
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 20,101
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 39,735
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 983
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,430
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 875
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,275
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 12,035
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 24,431
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 6,208
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 12,599
TX_PVLS Numerator: Indication: Routine 2017 20,101
TX_PVLS Numerator: Indication: Routine 2017 39,735
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,096
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,594
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 971
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,417
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 13,376
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 27,149
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 6,888
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 13,988
TX_PVLS_den Denominator: Indication: Routine 2017 22,331
TX_PVLS_den Denominator: Indication: Routine 2017 44,148
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 46
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 92
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 79
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 149
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 82
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 160
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 74
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 144
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 94
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 185
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 347
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 677
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 14
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 33
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,003
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,956
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,294
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,472
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 80
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 150
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 784
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,518
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 95
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 187
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 112
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 220
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,504
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,927
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,186
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,208
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 4,897
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 9,542
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 5,501
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 10,723
TX_RET_den Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 51
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 101
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 85
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 163
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 87
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 178
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 82
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 167
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 106
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 208
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 389
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 760
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 719
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,393
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,133
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,211
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,577
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,021
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 91
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 164
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 180
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 351
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 102
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 206
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 122
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 242
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,695
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,302
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,582
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,973
Cross Cutting Budget Categories and Known Amounts Total: $130,000
Key Populations: MSM and TG $30,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Gender: Gender Equality $50,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Promoting gender-related policies and laws that increase legal protection
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Based Violence (GBV) $50,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation